NDTDI

NDTDI
Clinical data
Other names	N-(2-Diethylcarbamoylethyl)-N-methyl-4,α-methylenetryptamine; N-(3-Diethylamino-3-oxopropyl)-N-methyl-4,α-methylenetryptamine; 9-Nor-LSD; 9-Desmethine-LSD; 8,10-Seco-LSD
Drug class	Serotonergic psychedelic; Hallucinogen; Simplified/partial LSD analogue
ATC code	None;
Legal status
Legal status	Illegal in Latvia;
Identifiers
	IUPAC name N,N-diethyl-3-(methyl(1,3,4,5-tetrahydrobenzo[cd]indol-4-yl)amino)propanamide;
PubChem CID	163192742;
CompTox Dashboard (EPA)	DTXSID601342245 ;
Chemical and physical data
Formula	C19H27N3O
Molar mass	313.445 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)C(=O)CCN(C)C1Cc3cccc2ncc(C1)c23;
	InChI InChI=1S/C19H27N3O/c1-4-22(5-2)18(23)9-10-21(3)16-11-14-7-6-8-17-19(14)15(12-16)13-20-17/h6-8,13,16,20H,4-5,9-12H2,1-3H3; Key:JECGWOMOCPQHDH-UHFFFAOYSA-N;

NDTDI, also known as 9-desmethine-LSD, 9-nor-LSD, or 8,10-seco-LSD, is a psychedelic drug related to lysergic acid diethylamide (LSD). It is a tricyclic cyclized tryptamine and partial lysergamide and is a structurally simplified analogue of LSD. The drug is specifically the analogue of LSD in which the carbon atom at position 9 of the ergoline ring system has been removed. It has been reported to produce psychedelic effects similarly to LSD, but with much lower potency. The pharmacology of NDTDI has not been studied. NDTDI was encountered as a novel designer drug by 2016.